A dominant, ultra-high-margin surgical quality “gold standard” at an inflection point—guidelines, direct sales, and vascular expansion can turn adoption into an annuity-like growth engine.
Overview
Medistim ASA is a Norway-based niche medtech leader and widely regarded “gold standard” for intraoperative quality assessment in cardiac, vascular and transplant surgery. Over ~40 years it has built proprietary ultrasound platforms (MiraQ/VeriQ) combining Transit Time Flow Measurement (TTFM) and High-Frequency Ultrasound (HFUS) imaging to give surgeons real-time, objective verification of surgical outcomes—reducing complications and costly re-interventions. The model is high-quality: capital console placements create an installed base that drives recurring consumables (probes/smartcards) and, increasingly, pay-per-procedure (PPP) revenue, with third-party distribution adding stability in Scandinavia. Scale and penetration are meaningful (4,000+ systems; used in ~40% of ~700k CABG procedures globally), yet the biggest opportunity remains converting the unserved portion of the market—particularly the US. 2025 was a breakout year: record revenue MNOK 699.8 (+24.4%) with strong operating leverage (EBIT MNOK 196.2, +50%; margin 28%). Medistim enters 2026 with a net cash balance sheet (MNOK 212.1 cash, no debt) and a long dividend track record (proposed NOK 8.00/share), funding expansion into direct-sales markets and further clinical validation (SMARTFLOW trial).